I spent last week on the road, first visiting our office in India and then onto London for a board and shareholder meeting. As I jetted home across the Atlantic to California, it was hard not to reflect on how far Advera Health Analytics has come in the past two years.

Last week we published a research report that exemplifies the sum of our efforts over these past couple of years. This report focused on Hepatitis C medications and highlighted how Abbvie’s Viekira Pak is showing initial signs of more costly and serious adverse events than its chief competitor, Gilead’s Harvoni. It is the only publicly available, independent report on the post marketing experience of patients on Hep C medications, and the findings are meaningful and I urge you to read the report here if you haven’t already.

To produce that report, the raw adverse event data were collected from a Freedom of Information Act request. It’s a cumbersome process that includes machine reading PDF files and then cleansing and optimizing the data through our RxFilter process. The clean data were then subjected to our RxScore, RxCost, and RxSignal analytic tools to spotlight the critical findings that our analysts could then review in preparing the report. Maybe most impressive was that the report reflected the cumulative effort of our tech, data and analyst teams to turn a lot of messy data into cohesive analysis and comprehensive findings in a short period of time.

While the findings were impactful, what excites me most is that the report utilized a number of proprietary analytics, tools, and methodologies that simply weren’t possible two years ago. At this point in 2013, most of our analytics were in alpha testing and we hadn’t even begun to think about FOIA requests and the extra effort of processing those data. Since then, our data methodologies have improved by quantum leaps, our analytics have been refined and tested, and RxFilter, RxCost, and RxScore have undergone scientific validation through peer review and publication in major journals (with RxSignal on its way through that process).

Over the past years, we’ve heard from countless people that have said that what we’re doing can’t, shouldn’t, and won’t work. But it’s amazing what a little bit of vision and a whole lot of hard work can produce. Ideas that started out on a whiteboard two and three years ago have become operational realities being utilized by some of the leading healthcare institutions in this country. They are using these data to identify the unforeseen medical costs linked to serious non-labeled adverse events and to make formulary and prescription changes as a result. For the first time they know definitely which drug costs more from time of prescription through its lifespan with a patient. To those who said it wasn’t possible, we’ve happily proven them wrong. We are proud that a positive impact can be made both in terms of costs and outcomes by reacting to these data..

In the little bit of downtime we had in London, my co-founder Bob Kyle and I had the opportunity to go see a soccer (FOOTBAL!!) match at White Hart Lane between my beloved Tottenham Hotspurs and Liverpool.

The Spurs’ motto is “To Dare Is To Do” – and I think that’s just as applicable to Advera Health Analytics. It’s taken quite a bit of daring to get to this point and we’re just getting started. The vision we have goes well beyond the mountain of work we’ve already done. We have plans to integrate more critical datasets into our analytics platform, to create and refine new and innovative ways to extract actionable intelligence from those data, and to continue to build out a world class team.

We hope that you’ll continue to follow our journey as we dare to do.

To learn more about how organizations across the healthcare system reduce costs please click here.

Click here to obtain access to the latest report analyzing the post-marketing experience of Viekira Pak and Harvoni.

 

 



Brian Overstreet

Brian Overstreet

President

Robert Kyle Linkedin twitter

Brian Overstreet

Written by Brian Overstreet